Literature DB >> 21303408

Serum pepsinogen II: a neglected but useful biomarker to differentiate between diseased and normal stomachs.

Cai-yun He1, Li-ping Sun, Yue-hua Gong, Qian Xu, Nan-nan Dong, Yuan Yuan.   

Abstract

BACKGROUND AND AIM: Serum pepsinogen II (sPGII) is underutilized and considered an inconspicuous biomarker in clinical practice. We refocused on this neglected but novel biomarker and conducted the present study, aiming to elucidate the normal level of sPGII in healthy Chinese patients and to investigate the clinical utility of sPGII for gastric disease screening.
METHODS: In 2008-2009, a total of 2022 participants from northern China were selected and enrolled in the study. sPGII and Helicobacter pylori (H. pylori)-immunoglobulin G were measured with ELISA.
RESULTS: sPGII showed a normal value of 6.6 microg/L in a total of 466 patients with endoscopically- and histologically-normal stomachs. A small sex difference was observed: the average value of sPGII was 7 microg/L and 6 microg/L in males and females, respectively (P < 0.001). In the differentiation between healthy and diseased (endoscopically-diseased stomach or gastritis/atrophic gastritis in endoscopic biopsies) stomach mucosae, the best sPGII cut-off value was 8.25 microg/L (sensitivity 70.6%, specificity 70.8%). In screening the H. pylori seropositivity, the optimum cut-off sPGII value was 10.25 microg/L (sensitivity 71.6%, specificity 70.1%).
CONCLUSIONS: We demonstrated that the mean values of sPGII in a healthy Chinese population are 7 microg/L and 6 microg/L for males and females, respectively. sPGII significantly increases in diseased and H. pylori-infected stomach, and the best sPGII cut-off value is 8.25 microg/L in the differentiation between patients with healthy and diseased stomach mucosae. Furthermore, Chinese patients with sPGII greater than 10.25 microg/L are at greater risk of various H. pylori-related gastropathies, and are therefore prior candidates for gastro-protection therapy.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303408     DOI: 10.1111/j.1440-1746.2011.06692.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

1.  Serum pepsinogen II is a better diagnostic marker in gastric cancer.

Authors:  Xue-Yuan Cao; Zhi-Fang Jia; Mei-Shan Jin; Dong-Hui Cao; Fei Kong; Jian Suo; Jing Jiang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

2.  Helicobacter pylori infection affects immune responses following vaccination of typhoid-naive U.S. adults with attenuated Salmonella typhi oral vaccine CVD 908-htrA.

Authors:  Khitam Muhsen; Marcela F Pasetti; Mardi K Reymann; David Y Graham; Myron M Levine
Journal:  J Infect Dis       Date:  2013-11-23       Impact factor: 5.226

3.  PGC-MG7 combination could be used as a follow-up panel for monitoring dynamical progression of gastric precancerous diseases.

Authors:  Peifang Ning; Liping Sun; Nannan Dong; Yuan Yuan
Journal:  Chin J Cancer Res       Date:  2020-02       Impact factor: 5.087

4.  Seroprevalence of Helicobacter pylori/CagA Antibodies in Guatemalan Gastric Cancer Patients: Association of Seropositivity with Increased Plasma Levels of Pepsinogens but not Soluble Urokinase Plasminogen Activator Receptor.

Authors:  Rafael Fernandez-Botran; Irmgardt Alicia Wellmann; Clas Une; Ericka Méndez-Chacón; Elisa Hernández de Rodas; Bikash Bhandari; Carmen I Villagrán de Tercero
Journal:  Am J Trop Med Hyg       Date:  2020-04-16       Impact factor: 2.345

5.  Gastric atrophy and oesophageal squamous cell carcinoma: possible interaction with dental health and oral hygiene habit.

Authors:  D Nasrollahzadeh; R Malekzadeh; K Aghcheli; M Sotoudeh; S Merat; F Islami; F Kamangar; C C Abnet; R Shakeri; A Pourshams; S Semnani; P Boffetta; S M Dawsey; W Ye
Journal:  Br J Cancer       Date:  2012-07-19       Impact factor: 7.640

6.  Accuracy and cut-off values of pepsinogens I, II and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis.

Authors:  Dariush Nasrollahzadeh; Karim Aghcheli; Masoud Sotoudeh; Ramin Shakeri; E Christina Persson; Farhad Islami; Farin Kamangar; Christian C Abnet; Paolo Boffetta; Lars Engstrand; Sanford M Dawsey; Reza Malekzadeh; Weimin Ye
Journal:  PLoS One       Date:  2011-10-31       Impact factor: 3.240

7.  Mitogen-activated protein kinase activator with WD40 repeats (MAWD) and MAWD-binding protein induce cell differentiation in gastric cancer.

Authors:  Dongmei Li; Jun Zhang; Yu Xi; Lei Zhang; Wenmei Li; Jiantao Cui; Rui Xing; Yuanmin Pan; Zemin Pan; Feng Li; Youyong Lu
Journal:  BMC Cancer       Date:  2015-09-15       Impact factor: 4.430

8.  Expression of serum miR-20a-5p, let-7a, and miR-320a and their correlations with pepsinogen in atrophic gastritis and gastric cancer: a case-control study.

Authors:  Qian Xu; Qi-Guan Dong; Li-Ping Sun; Cai-Yun He; Yuan Yuan
Journal:  BMC Clin Pathol       Date:  2013-03-22

9.  Serum Indicators Reflecting Gastric Function May Also Correlate with Other Extragastric Diseases.

Authors:  Yuehua Gong; Wei Wang; Yi Li; Yuan Yuan
Journal:  Gastroenterol Res Pract       Date:  2015-08-03       Impact factor: 2.260

Review 10.  Significance of Serum Pepsinogens as a Biomarker for Gastric Cancer and Atrophic Gastritis Screening: A Systematic Review and Meta-Analysis.

Authors:  Ya-kai Huang; Jian-chun Yu; Wei-ming Kang; Zhi-qiang Ma; Xin Ye; Shu-bo Tian; Chao Yan
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.